Delcath reported third-quarter 2026 revenue of $35.1 million, net income of $7 million and adjusted EBITDA of $11.5 million, and raised full-year 2026 revenue guidance to $115 million to $117 million.
DCTH · Delcath Systems, Inc.
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Key stats
- Close
- $19.24
- Open
- $19.89
- Day range
- $18.99–19.89
- 52-week closing range
- $8.19–21.77
- Average volume, 30 days
- 633K
- Short interest
- 1.8M · 5.1% of shares · 5.7 days
- Short volume, last session
- 44%
- Last earnings
- Nov 9, 2026
- Latest filing
- 10-Q · Nov 9
- Price history
- Jan 2020 to Nov 2026
Up next
Latest documents
Delcath Systems reported nine-month revenue of $89,229 thousand versus $64,503 thousand and net income of $8,550 thousand versus $4,596 thousand, driven by continued U.S. commercial expansion and demand for HEPZATO.
Delcath Systems, Inc. reported third-quarter 2026 revenue of $35.1 million, net income of $7.0 million, increased 2026 revenue guidance to $115 million to $117 million, and held $104.3 million in cash and investments with no debt.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
AI Brief
Q3 FY26 earnings call · Nov 9, 2026TL;DR. Revenue reached a record $35.1 million, margins and profitability improved, cash generation strengthened, the center network expanded, and full-year revenue guidance was raised. Breast-cancer enrollment remains slower than anticipated, fourth-quarter guidance includes a holiday-related step-down, R&D spending is expected to rise, SG&A expense increased, and new-center activation carries uncertainty.
- + Third-quarter revenue reached a record $35.1 million.
- + Full-year 2026 revenue guidance was raised to $115 million to $117 million.
- + Gross margin improved to 89% from 87%.
- + Net income increased to $7 million and adjusted EBITDA increased to $11.5 million.
- + The company generated $8.2 million from operations and ended with $104.3 million in cash and investments and no debt.
- + The treatment-center network expanded, with at least 36 centers expected by year-end.
- − Breast-cancer trial enrollment has been slower than anticipated, and interim-analysis timing is not yet guided.
- − R&D spending is expected to increase quarter over quarter into 2027.
- − Fourth-quarter guidance includes a holiday-related step-down.
- − Quarterly profitability may vary as investment continues.
- − New-center activation carries uncertainty because scheduled procedures can be canceled.
- − SG&A expense increased to $13.1 million from $10.3 million year over year.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Cash and investments | $104.3M | as of September 30, 2026 | — |
| Cash provided by operations | $8.2M | the quarter ended September 30, 2026 | — |
| CHEMOSAT revenue | $2.4M | third quarter 2026 | — |
| Gross margins | 89% | third quarter 2026 | — |
| HEPZATO KIT revenue | $32.7M | third quarter 2026 | +69.8% |
|
|
|||
| HEPZATO volume growth | 72% | third quarter 2026 compared to the third quarter 2025 | — |
|
|
|||
| Non-GAAP adjusted EBITDA non-GAAP | $11.5M | third quarter 2026 | — |
|
|
|||
| Active treatment centers | 31 | second quarter 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
DCTH
this stock
Delcath Systems, Inc.
|
$669.32M | +90.5% | +129.1% | 120.3 | 5.1% |
|
ABT
Abbott Laboratories
|
$179.90B | -17.1% | +5.7% | 38.8 | 1.1% |
|
MDT
Medtronic plc
|
$128.69B | +4.7% | +8.4% | 24.8 | 1.8% |
|
SYK
Stryker Corp
|
$119.19B | -10.9% | +11.2% | 33.3 | 1.7% |
|
BSX
Boston Scientific Corp
|
$62.31B | -54.9% | +12.5% | 18.2 | 2.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 9, 2026
- This year
- 15
Delcath Systems reported nine-month revenue of $89,229 thousand versus $64,503 thousand and net income of $8,550 thousand versus $4,596 thousand, driven by continued U.S. commercial expansion and demand for HEPZATO.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| DCTH | -10.0% | +30.4% | +81.5% | +37.0% | +90.5% |
| SPY | -5.5% | -6.3% | -5.6% | -5.3% | +5.0% |
| vs SPY | -4.6% | +36.7% | +87.1% | +42.3% | +85.5% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.